As important advances take place in health research and product development, it is crucial to ensure that promising new pipeline technologies can be successfully brought to market through continued and strategic investments. Through multisectoral capacity strengthening, ADP supports low- and middle-income countries to ensure that once new technologies are available, they can be swiftly introduced and made available to people who need them.
Limitations in access to new health technologies can be partly attributed to insufficient technical capacities in low- and middle-income countries (LMICs). At the same time, there is also a critical need for integrated approaches to help ensure that the various elements of in-country systems work together effectively and are drivers of improved access and delivery.
Acknowledging that multiple disciplines and partners are critical across the value chain of access and delivery, the ADP promotes three principles – country ownership to ensure long-term sustainability and address priorities defined by country stakeholders, cross-sectoral and multi-stakeholder collaborations to represent various perspectives from multiple sectors that are critical across the value chain, and South-South learning and cooperation to ensure mutual knowledge exchange and learning.
Working together with this approach, the ADP partners leverage the expertise of each organization and, within focus countries, draw on the full range of technical skills necessary to strengthen the value chain for the introduction and scale-up of new health technologies. The value chain that ADP functions across can be explored below, along with highlights of ADP’s previous work in these priority areas.
ADP supported the development of Ghana’s new National Medicines Policy, which provides a guiding framework for pharmaceuticals in Ghana for cost-effective introduction and timely delivery of health technologies. Through multi-stakeholder consultations, ADP enabled coordinated action across sectors for the effective implementation of the policy.
ADP is supporting the strengthening of national regulatory authorities and the national adoption of the African Union (AU) Model Law on Medical Products Regulation to promote regulatory harmonization and enables quicker approval and introduction of new, quality-assured health technologies.
ADP has supported the institutionalization of Health Technology Assessment in its focus countries as a systematic priority-setting process, enabling evidence-based decision making on new health technologies.
ADP is working with focus countries on strengthening systems and approaches to planning, procurement and pricing of health technologies to promote cost-effectiveness and access.
ADP has strengthened the supply chain of NTD medicines for Mass Drug Administration (MDA) campaigns in focus countries, through development of guidelines and roll-out of training tools for community-based health workers and volunteers in these countries.
ADP has promoted effective service delivery through the Implementation Research (IR) Toolkit, which enables countries to identify and address barriers to the operational use and scale-up of new technologies, and the development of national IR strategies and agendas.
ADP has helped establish drug safety monitoring systems and contributed to the training of health personnel in focus countries on the identification and appropriate management of unwanted side-effects of new medicines.